PeproTech Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McManus, L. M.
Right arrow Articles by Pinckard, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McManus, L. M.
Right arrow Articles by Pinckard, R. N.
(Journal of Leukocyte Biology. 2001;70:395-404.)
© 2001 by Society for Leukocyte Biology

Agonist-dependent failure of neutrophil function in diabetes correlates with extent of hyperglycemia

Linda M. McManus*,{dagger}, Rebecca C. Bloodworth*, Thomas J. Prihoda*,{ddagger}, Janet L. Blodgett§ and R. Neal Pinckard*,§

Departments of
* Pathology,
{dagger} Periodontics,
{ddagger} Psychiatry, and
§ Medicine, The University of Texas Health Science Center and
|| South Texas Veterans Administration Hospital, San Antonio, Texas

Correspondence: Linda M. McManus, Department of Pathology—MSC 7750, The University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900. E-mail: mcmanus{at}uthscsa.edu

Inexplicable controversies with regard to possible functional defects of neutrophilic polymorphonuclear leukocytes (PMNs) in diabetes persist. The purpose of the present study was to elucidate the relative effectiveness of several PMN agonists in stimulating lysosomal-enzyme secretion and leukotriene (LT) B4 production by PMNs isolated from diabetic subjects. Formyl-methionyl-leucyl-phenylalanine (fMLP) and platelet-activating factor (PAF) induced significantly less lysosomal-enzyme secretion and LTB4 production in diabetic-subject PMNs than in normal-subject PMNs. It is surprising that PMNs from these same diabetic subjects responded normally after stimulation with A23187, serum-opsonized zymosan, or phorbol myristate acetate. The in vitro responsiveness of PMNs stimulated with fMLP or PAF was inversely correlated with indices of in vivo glycemic control (fasting plasma glucose and glycated-hemoglobin levels). In combination, these results indicate that hyperglycemia is associated with sustained decreases in PMN function but only in response to agonists that initiate stimulus-response coupling via G-protein-coupled receptors. This agonist-selective reduction in PMN responsiveness may contribute to the compromised host defense associated with sustained hyperglycemia in diabetes.

Key Words: fMLP • GPCR • inflammation • LTB4 • PAF




This article has been cited by other articles:


Home page
Clin. DiabetesHome page
R. J. Comi, J. Jacoby, D. Basta, M. Wood, and J. Butterly
Improving Glucose Management by Redesigning the Care of Diabetic Inpatients Using a Nurse Practitioner Service
Clin. Diabetes, March 1, 2009; 27(2): 78 - 81.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
I. J. Tsai, L. J. Beilin, I. B. Puddey, K. D. Croft, and A. Barden
Impaired ex Vivo Leukotriene B4 Production Characterizes the Metabolic Syndrome and Is Improved after Weight Reduction
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4747 - 4752.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
N. W. Cheung, B. Napier, C. Zaccaria, and J. P. Fletcher
Hyperglycemia Is Associated With Adverse Outcomes in Patients Receiving Total Parenteral Nutrition
Diabetes Care, October 1, 2005; 28(10): 2367 - 2371.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch
Management of Diabetes and Hyperglycemia in Hospitals
Diabetes Care, February 1, 2004; 27(2): 553 - 591.
[Full Text] [PDF]


Home page
JAMAHome page
S. J. Finney, C. Zekveld, A. Elia, and T. W. Evans
Glucose Control and Mortality in Critically Ill Patients
JAMA, October 15, 2003; 290(15): 2041 - 2047.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
T. W. Evans
Hemodynamic and Metabolic Therapy in Critically Ill Patients
N. Engl. J. Med., November 8, 2001; 345(19): 1417 - 1418.
[Full Text] [PDF]